TGFBR2 Knockout HEK293 Cell Line
Cat.No.:
EDC07591
Species:
Human
Cell Name:
HEK293
Gene:
TGFBR2
Gene ID:
7048
Size:
1×10⁶cells
TGFBR2 Knockout Cell Line (HEK293) is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performance Cas9 Protein and Hassle-Free Cell Selection.
| Cat.No. | EDC07591 |
|---|---|
| Product Name | TGFBR2 Knockout Cell Line (HEK 293) |
| Cell Line | HEK293 |
| Cellosaurus ID | CVCL_0045 |
| Cell Line Synonyms | Hek293, HEK-293, HEK/293, (HEK)293, HEK 293, HEK,293, 293, 293 HEK, 293 Ad5, Graham 293, Graham-293, Human Embryonic Kidney 293 |
| Gene | TGFBR2 |
| NCBI Gene ID | |
| Gene Synonyms | AAT3|FAA3|LDS1B|LDS2|LDS2B|MFS2|RIIC|TAAD2|TBR-ii|TBRII|TGFR-2|TGFbeta-RII|tbetaR-II |
| Summary |
The protein encoded by this gene is a transmembrane protein that has a protein kinase domain, forms a heterodimeric complex with TGF-beta receptor type-1, and binds TGF-beta. This receptor/ligand complex phosphorylates proteins, which then enter the nucleus and regulate the transcription of genes related to cell proliferation, cell cycle arrest, wound healing, immunosuppression, and tumorigenesis. Mutations in this gene have been associated with Marfan Syndrome, Loeys-Deitz Aortic Aneurysm Syndrome, and the development of various types of tumors. Alternatively spliced transcript variants encoding different isoforms have been characterized. [provided by RefSeq, Aug 2017]
|
| Associated Diseases | Non-tumor |
| Morphology | Adherent |
| Passage Ratio | 1/5,2days |
| Complete Culture Medium | DMEM + 10% FBS |
| Freezing Medium | 95% Complete culture medium+ 5% DMSO |
| QC | Indels validated by Sanger sequencing; sterility confirmed via microbial testing. |
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
| Loci | STR Info (Sample Cell) Sample Cell Line: HEK293 | STR Info (Cell bank) Cell Line: HEK293 | ||
| Allele1 | Allele2 | Allele1 | Allele2 | |
| Amelogenin | X | X | ||
| CSF1P0 | 12 | 11 | 12 | |
| D2S1338 | 19 | 19 | ||
| D3S1358 | 15 | 17 | 15 | 17 |
| D5S818 | 8 | 8 | 9 | |
| D7S820 | 11 | 12 | 11 | 12 |
| D8S1179 | 12 | 14 | 12 | 14 |
| D13S317 | 12 | 14 | 12 | 14 |
| D16S539 | 9 | 13 | 9 | 13 |
| D18S51 | 17 | 18 | 17 | 18 |
| D19S433 | 15 | 18 | 15 | 18 |
| D21S11 | 28 | 30.2 | 28 | 30.2 |
| FGA | 23 | 23 | ||
| Penta D | 9 | 10 | 9 | 10 |
| Penta E | 7 | 15 | 7 | 15 |
| TH01 | 7 | 9.3 | 7 | 9.3 |
| TPOX | 11 | 11 | ||
| vWA | 16 | 19 | 16 | 19 |
| D6S1043 | 11 | 11 | ||
| D12S391 | 19 | 21 | 11 | 15 |
| D2S441 | 11 | 15 | 11 | 15 |
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.
Conclusion: The STR identification of this cell is correct.
FAQ
Which is better for studying TGFBR2 function, TGFBR2 Knockout HEK293 Cell Line or TGFBR2 overexpression HEK293 Cell Line?
The choice depends on whether you are studying TGF-β signaling cascade biology or modeling TGFBR2 loss-of-function in disease contexts (Loeys-Dietz syndrome, microsatellite-instable cancers). The Knockout line is the standard tool for asking whether TGFBR2 is required for SMAD2/3 phosphorylation and downstream TGF-β responses. Overexpression is useful for studying disease-associated TGFBR2 missense mutations or constitutively active variants.
For TGF-β pathway research, the EDITGENE TGFBR2 Knockout in HEK293 is a mechanistic platform — HEK293 has a long history in TGF-β signaling research, supporting SMAD reporter assays and rescue with structural variants. Rescue with wild-type, kinase-dead, or disease-mutant TGFBR2 enables structure-function studies and disease modeling.
What are the application scenarios for this model?
Primary applications:
• SMAD signaling: phospho-SMAD2/3 Western blot and SMAD-responsive reporter (CAGA-luc) assays to assess TGFBR2-dependent canonical TGF-β signaling.
• TGF-β responsive gene expression: analysis of canonical TGF-β target genes (PAI-1, SMAD7, p15/CDKN2B) following TGF-β stimulation.
• Disease mutation rescue: introduction of Loeys-Dietz syndrome-associated TGFBR2 mutations or MSI-associated truncating mutations for genotype-function studies.
• Non-canonical TGF-β signaling: TAK1, MAPK, and PI3K activation analysis to assess TGFBR2-dependent non-SMAD pathways.
EDITGENE recommends this model for researchers investigating TGF-β signaling biology, Loeys-Dietz syndrome, and TGFBR2-related cancer biology.
Is this TGFBR2 Knockout HEK293 Cell Line compatible with overexpression rescue experiments?
Yes. TGFBR2 rescue experiments are well-established in TGF-β pathway research:
• Construct design: use a codon-modified TGFBR2 sequence with a cytoplasmic C-terminal tag (FLAG, HA). TGFBR2 is a type I membrane serine/threonine kinase — extracellular ligand-binding domain and intracellular kinase domain must both be preserved.
• Kinase-dead rescue: the K277R mutation in the active site lysine abolishes kinase activity and is the standard control for distinguishing kinase from receptor-binding functions.
• Disease mutation rescue: Loeys-Dietz syndrome-associated TGFBR2 mutations or MSI-associated frameshift mutations enable genotype-function studies.
• Functional readout: rescue should restore TGF-β-induced SMAD2/3 phosphorylation (Western blot) and CAGA-luc reporter activity.
HEK293 transduces efficiently with lentivirus and has established protocols for TGF-β pathway rescue experiments.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.
download